by Kelley Tracy | Jun 6, 2018 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I STTR from the National Institute of Drug Abuse Entitled “Trigriluzole for the Treatment of Cocaine Abuse” Doylestown, PA. June 6, 2018 – FCCDC is pleased to report...
by Kelley Tracy | May 31, 2018 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a 2-year Phase I STTR from the National Institute of Arthritis and Infectious Disease Entitled “Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever” Doylestown, PA....
by Kelley Tracy | Sep 12, 2017 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase II SBIR from the National Institute of Aging (NIA) Entitled “PET Imaging Agents for the in vivo Detection of TDP-43” Doylestown, PA. September 12, 2017- FCCDC is pleased to...
by Kelley Tracy | Jun 27, 2017 | Uncategorized
The Fox Chase Chemical Diversity Center has Completed Participation in the NIH Commercialization Accelerator Program (CAP), Based Upon NIH Grant #R44 AI125005-02 (“Development of Topical Antiviral Agents for Treating Molluscum contagiosum”) Doylestown, PA....
by Kelley Tracy | May 25, 2017 | Uncategorized
The Fox Chase Chemical Diversity Center Annonuces the U.S. Food and Drug Administration Has Provided Fast-Track Designation to Trigriluzole for the Treatment of Ataxia. Trigriluzole, Also Known As FC-4157 and BHV-4157, is an Investigational New Drug Being Developed by...
by Kelley Tracy | Apr 21, 2017 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I STTR Entitled “Inhibitors of Hydrogen Sulfide Metabolism as a Novel Treatment for Heart Failure,” Prof. Marilyn S. Jorns of Drexel University College of Medicine, Principal...
